Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 4Thoracic 1Genitourinary 1Gastrointestinal 1CNS 1Breast 1

Conditions

Glioma 9Neuroblastoma 8Breast Neoplasms 6Neoplasms 5Thyroid Cancer, Papillary 4Sarcoma 4Neurofibroma, Plexiform 4Central Nervous System Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Brain Neoplasms 4Thyroid Neoplasms 3Pheochromocytoma 3Paraganglioma 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Neurofibromatosis 1 3Lung Neoplasms 3Head and Neck Neoplasms 3Glioblastoma 3Colonic Neoplasms 3Carcinoma, Renal Cell 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Thyroid Diseases 2Thoracic Neoplasms 2Salivary Gland Neoplasms 2Respiratory Tract Neoplasms 2Respiratory Tract Diseases 2Neuroendocrine Tumors 2Neoplasms by Site 2

Interventions

sacituzumab govitecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × Carcinoma, Ovarian Epithelial × CNS × Clear all
NCT01631552 2021-08-12

Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer

Gilead Sciences

Phase 1/2 Completed
515 enrolled 28 charts 1 FDA
BreastCNSGastrointestinalGenitourinaryGynecologicThoracic

Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Carcinoma, Hepatocellular, Pancreatic Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡